Phenothiazine Drugs

Total Page:16

File Type:pdf, Size:1020Kb

Phenothiazine Drugs Proc. Nat. Acad. Sci. USA Vol. 72, No. 5, pp. 1899-1903, May 1975 Phenothiazine Drugs: Structure-Activity Relationships Explained by a Conformation That Mimics Dopamine (catecholamine/neurotransmitter/receptor/chlorpromazine/schizophrenia) ANDREW P. FEINBERG AND SOLOMON H. SNYDER Departments of Pharmacology and Experimental Therapeutics and Psychiatry and the Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205 Communicated by Seymour S. Kety, February 21, 1975 ABSTRACT The antischizophrenic activity of pheno- perphenazine, and fluphenazine were constructed with Corey- thiazine drugs and their tendency to elicit extrapyramidal Pauling-Koltun kits (Ealing Corp.; Cambridge, Mass.). To symptoms are thought to involve blockade of synaptic dopamine receptors in the brain. Space filling molecular confirm the apparent influence of Van der Waal's forces on the models show how favorable Van der Waal's interactions side chain conformation, we performed potential energy calcu- between the side chain amino of phenothiazines and the 2- lations on the following three compounds with differing ring substituent on ring A can promote a conformation mim- substituents but the same side chain: promazine, chlorpro- icking dopamine. These Van der Waal's attractive forces can explain (i) the greater potency of drugs with trifluoro- mazine, and triflupromazine. Calculations were performed on methyl rather than chlorine as a 2-substituent; (ii) the alkylamino side chain phenothiazines, since the great increase enhanced activity of phenothiazines with piperazine in- in conformational variables introduced by a flexible piperidine stead of alkylamino side chains; (iii) the increased po- or piperazine ring was beyond the practical capability of the tency associated with hydroxyethylpiperazines as con- trasted to piperazine side chains ; (iv) the greater potency computer. of cis rather than trans thioxanthenes; and (v) the crucial The calculations were performed on a PDP-12 computer location of the ring A substituent at carbon no. 2. Poten- with floating point processor and 8K of memory, using a form tial energy calculations support the observations with of the Buckingham 6-exp potential function proposed by molecular models and suggest an active conformation for A. I. Kitaygorodskii (8): the phenothiazines. V = 3.5 (8600 e-13Z- 0.04 Z-6) An abundance of recent research suggests that a major mechanism whereby antischizophrenic phenothiazine drugs where z is the ratio of the distance between atom centers and exert their therapeutic actions and extrapyramidal side effects G. N. Ramachandran's K2 values for Van der Waal's radii (9). observed involves a blockade of synaptic receptor sites for dopamine in This function has shown good agreement with x-ray the brain (1, 2). The activity of a dopamine-sensitive adenylate crystal structures (10). cyclase correlates with dopamine receptor activity (3). Rela- Two groups of computer programs, developed at Washing- tive potencies of several phenothiazine and related drugs as ton University Computer Systems Laboratory, were used. inhibitors of the dopamine-sensitive adenylate cyclase parallel The first group, CHEMAST (11, 12), was used to generate their antischizophrenic potency (4-6). Earlier we proposed a lists of atomic coordinates, atom types, connectivity and rota- molecular model wherein dopamine could be superimposed tion parameters, and stereoscopic images of the molecules on upon a portion of the chlorpromazine molecule (7). While ex- a point-plotting cathode ray tube. The second group, BUR- plaining some structure-activity characteristics of pheno- LESK (13, 14), was used to perform iterative rotations over thiazines, this model did not deal with important features the bonds indicated in Fig. 1 and the trifluoromethyl group such as the greater potencies of phenothiazines with piperazine in triflupromazine, computing the potential energy between rather than alkylamino side chains, nor did it explain the all atom pairs whose relative orientations were changed by the greater potency of trifluoromethyl than of chlorine ring sub- rotations; and to display the data on the cathode ray tube stituents. Moreover, it provided no explanation for the mech- as isoenergy curves. To obviate calculations on absurd con- anism whereby the A ring substituent caused the side chain formers, the programs made a "bump check", for which Van to tilt toward the A ring, nor did it explain why the A ring der Waal's radii were set at 90% of those used by Leach et al. substituent must be located in the number 2 position. (15). The data were compared to control data obtained with- In the present study, Corey-Pauling-Koltun molecular out a "bump check" to ascertain that no legitimate con- models and computer calculations support a model in which formers were excluded. phenothiazines assume a conformation that mimics that of A special connectivity table was prepared for the pheno- dopamine, explaining the role of trifluoromethyl, piperazine, thiazine ring system (16), and its bond lengths and bond and hydrox-yethvlpiperazine groups as well as the mechanism angles were obtained from the published crystal structure of whereby A ring substituents influence the side chain. thiethylperazine (17). It might have been more natural to use published data on chlorpromazine (18), but these yielded MATERIALS AND METHODS bizarre ring atom placements. Molecular models of promazine, chlorpromazine, triflu- For each molecule, between 16,000 and 150,000 conforma- promazine, prochlorperazine, trifluoperazine, thiethylperazine, tions were examined using 5-15 hr of computer time. In criti- 1899 Downloaded by guest on September 26, 2021 1900 Medical Sciences: Feinberg and Snyder Proc. Nat. Acad. Sci. USA 72 (1975) 4 5 19l 9 20 CH3 (ECH2\ 'qH2-C1 I*He 4 T3 162 CH3 19 T, a T(C,,-NO-C15"C16 ) T2=aT (NI0_CI5 -C6 -CI7 ) T3 T(Ci5-CI6-CI7-NIS) a T(C16-CI7 -N18 -C19) FIG. 1. Rotatable bonds of chlorpromazine, drawn with T1. =2 = T4 = 00 and T3 = 1800. The convexity of the pheno- thiazine ring system is upward. The torsion angle r(A-X-Y-B) is the dihedral angle between planes AXY and XYB, measured clockwise when viewed down the bond X-Y (25). cal regions, the data were compared to control data obtained C over a greater density of conformations to confirm their completeness. A Hewlett-Packard 7005B X-Y Recorder was used to draw the isoenergy curves on graph paper, and they were then re- traced. The figures of ball and stick models were made with a DECSYSTEM 10 time-sharing computer, AGT-30 ADAGE graphics system, and model 200 ZETA plotter, using the program package CHEM (19), and they were then redrawn by an artist. RESULTS AND DISCUSSION Space-filling models of chlorpromazine (Fig. 2) reveal that tilting of the side chain toward ring A permits favorable Van der Waal's interactions of the side chain with the chlorine substituent. These Van der Waal's attractive forces would be greatly lessened in the case of promazine, which lacks the chlorine substituent. This conformation permits the super- imposition of dopamine (Fig. 3), thus explaining how chlor- promazine can interact with dopamine receptors. The space- filling models provide a causal explanation for the folding of the side chain toward ring A. FIG. 2. Phenothiazines with the side chain "tilted" toward The notion that Van der Waal's attractions between the the A ring, drawn with relatively small atom size for ease of side chain and the ring A substituent could account for the viewing. ri and T2 are set at (-68°, 1350), the relative minimum of conformational zone no. 2 in Fig. 5. (a) Chlorpromazine (the ability of phenothiazines to assume the dopamine-like con- side chain N to Cl distance is 3.3 A); (b) triflupromazine formation allows several about the structure of (the predictions distance of the side chain N to the closest fluorines is 3.0-3.5 A); phenothiazines that might be expected to be more or less po- (c) trifluoperazine; (d) fluphenazine. tent in interactions with the dopamine receptors. For instance, this model requires that the ring A substituent be located at the chlorine substituent. Our model predicts that pheno- the number 2 position. A 1-substituent would sterically hinder thiazines with trifluoromethyl substituents should be more the ability of the side chain to approach ring A, while a 3- potent than those with chlorine substituents. Of the clinically substituent would be too distant from the side chain to pro- used phenothiazines, those with trifluoromethyl substituents vide Van der Waal's attractions of a significant degree. Exten- at position 2 of ring A are uniformly more potent than those sive experience with many phenothiazine structures has shown with chlorine substituents, both clinically and in their inhibi- that optimal neuroleptic activity occurs only when the ring A tion of the dopamine-sensitive adenylate cyclase (4-6, 20, 21). substituent is in the 2-position (20, 21). The nature of the atom in proximity to the side chain amine The nature of the 2-substituents in our model would be might also be anticipated to influence the conformation of the expected to influence the conformation of the side chain. A phenothiazine side chain. A piperazine side chain affords more trifluoromethyl substituent provides a greater number of Van der Waal's contacts with the 2-substituent than does an favorable Van der Waal's contacts with the side chain than alkylamino side chain (Fig. 2). The resultant predictions that Downloaded by guest on September 26, 2021 Proc. Nat. Acad. Sci. USA 72 (1975) Phenothiazines and Dopamine 1901 TABLE 1. Phenothiazine and thioxanthene drug structures and effects on a dopamine-sensitive adenylate cyclase Relative potency in inhibiting dopamine-sensitive adenylate cyclase of rat corpus striatum (chlorpromazine = 100) t Relative Results of Results of clinical Miller and Clement-Courmier Drug Ring R, R2 potency* Iversen (5) et al. (4) Ca-Flupenthixol thio. HEP CF3 1 4545 (aO6)-Flupenthixol thio.
Recommended publications
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • Adverse Reactions to Hallucinogenic Drugs. 1Rnstttutton National Test
    DOCUMENT RESUME ED 034 696 SE 007 743 AUTROP Meyer, Roger E. , Fd. TITLE Adverse Reactions to Hallucinogenic Drugs. 1rNSTTTUTTON National Test. of Mental Health (DHEW), Bethesda, Md. PUB DATP Sep 67 NOTE 118p.; Conference held at the National Institute of Mental Health, Chevy Chase, Maryland, September 29, 1967 AVATLABLE FROM Superintendent of Documents, Government Printing Office, Washington, D. C. 20402 ($1.25). FDPS PRICE FDPS Price MFc0.50 HC Not Available from EDRS. DESCPTPTOPS Conference Reports, *Drug Abuse, Health Education, *Lysergic Acid Diethylamide, *Medical Research, *Mental Health IDENTIFIEPS Hallucinogenic Drugs ABSTPACT This reports a conference of psychologists, psychiatrists, geneticists and others concerned with the biological and psychological effects of lysergic acid diethylamide and other hallucinogenic drugs. Clinical data are presented on adverse drug reactions. The difficulty of determining the causes of adverse reactions is discussed, as are different methods of therapy. Data are also presented on the psychological and physiolcgical effects of L.S.D. given as a treatment under controlled medical conditions. Possible genetic effects of L.S.D. and other drugs are discussed on the basis of data from laboratory animals and humans. Also discussed are needs for futher research. The necessity to aviod scare techniques in disseminating information about drugs is emphasized. An aprentlix includes seven background papers reprinted from professional journals, and a bibliography of current articles on the possible genetic effects of drugs. (EB) National Clearinghouse for Mental Health Information VA-w. Alb alb !bAm I.S. MOMS Of NAM MON tMAN IONE Of NMI 105 NUNN NU IN WINES UAWAS RCM NIN 01 NUN N ONMININI 01011110 0.
    [Show full text]
  • The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis
    The effects of antipsychotic treatment on metabolic function: a systematic review and network meta-analysis Toby Pillinger, Robert McCutcheon, Luke Vano, Katherine Beck, Guy Hindley, Atheeshaan Arumuham, Yuya Mizuno, Sridhar Natesan, Orestis Efthimiou, Andrea Cipriani, Oliver Howes ****PROTOCOL**** Review questions 1. What is the magnitude of metabolic dysregulation (defined as alterations in fasting glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels) and alterations in body weight and body mass index associated with short-term (‘acute’) antipsychotic treatment in individuals with schizophrenia? 2. Does baseline physiology (e.g. body weight) and demographics (e.g. age) of patients predict magnitude of antipsychotic-associated metabolic dysregulation? 3. Are alterations in metabolic parameters over time associated with alterations in degree of psychopathology? 1 Searches We plan to search EMBASE, PsycINFO, and MEDLINE from inception using the following terms: 1 (Acepromazine or Acetophenazine or Amisulpride or Aripiprazole or Asenapine or Benperidol or Blonanserin or Bromperidol or Butaperazine or Carpipramine or Chlorproethazine or Chlorpromazine or Chlorprothixene or Clocapramine or Clopenthixol or Clopentixol or Clothiapine or Clotiapine or Clozapine or Cyamemazine or Cyamepromazine or Dixyrazine or Droperidol or Fluanisone or Flupehenazine or Flupenthixol or Flupentixol or Fluphenazine or Fluspirilen or Fluspirilene or Haloperidol or Iloperidone
    [Show full text]
  • Guideline for the Treatment of Breakthrough and the Prevention of Refractory Chemotherapy-Induced Nausea and Vomiting in Children with Cancer
    This is a repository copy of Guideline for the Treatment of Breakthrough and the Prevention of Refractory Chemotherapy-induced Nausea and Vomiting in Children with Cancer. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/97043/ Version: Accepted Version Article: Flank, Jaqueline, Robinson, Paula, Holdsworth, Mark et al. (7 more authors) (2016) Guideline for the Treatment of Breakthrough and the Prevention of Refractory Chemotherapy-induced Nausea and Vomiting in Children with Cancer. Pediatric blood & cancer. ISSN 1545-5009 https://doi.org/10.1002/pbc.25955 Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Pediatric Blood & Cancer Guideline for the Treatment of Breakthrough and the Prevention of Refractory Chemotherapy-induced Nausea and Vomiting in Children with Cancer Journal: Pediatric Blood & Cancer Manuscript ID PBC-15-1233.R1 Wiley - ManuscriptFor
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya Et Al
    US 2006.0024.365A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya et al. (43) Pub. Date: Feb. 2, 2006 (54) NOVEL DOSAGE FORM (30) Foreign Application Priority Data (76) Inventors: Navin Vaya, Gujarat (IN); Rajesh Aug. 5, 2002 (IN)................................. 699/MUM/2002 Singh Karan, Gujarat (IN); Sunil Aug. 5, 2002 (IN). ... 697/MUM/2002 Sadanand, Gujarat (IN); Vinod Kumar Jan. 22, 2003 (IN)................................... 80/MUM/2003 Gupta, Gujarat (IN) Jan. 22, 2003 (IN)................................... 82/MUM/2003 Correspondence Address: Publication Classification HEDMAN & COSTIGAN P.C. (51) Int. Cl. 1185 AVENUE OF THE AMERICAS A6IK 9/22 (2006.01) NEW YORK, NY 10036 (US) (52) U.S. Cl. .............................................................. 424/468 (22) Filed: May 19, 2005 A dosage form comprising of a high dose, high Solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of Related U.S. Application Data immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of (63) Continuation-in-part of application No. 10/630,446, modified release active ingredient per unit is from 500 mg to filed on Jul. 29, 2003. 1500 mg, a process for preparing the dosage form. Patent Application Publication Feb. 2, 2006 Sheet 1 of 10 US 2006/0024.365A1 FIGURE 1 FIGURE 2 FIGURE 3 Patent Application Publication Feb. 2, 2006 Sheet 2 of 10 US 2006/0024.365A1 FIGURE 4 (a) 7 FIGURE 4 (b) Patent Application Publication Feb. 2, 2006 Sheet 3 of 10 US 2006/0024.365 A1 FIGURE 5 100 ov -- 60 40 20 C 2 4.
    [Show full text]
  • Testosterone for Women...And Men
    Testosterone for Women...and Men Date: 05/08/2006 Posted By: Jon Barron Every now and then I get a break in putting together a newsletter. I get to steal the entire newsletter from myself. In this case, I was able to take most of the material for this newsletter from the formulation information I put together for my new upgraded Women's Formula that Baseline Nutritionals released this month. And while this newsletter definitely serves as an introduction to that new formula, it more importantly provides an excuse for exploring a crucial topic for both men and women -- the value of maintaining an optimum testosterone balance. However, before we get into the specifics of both the men's and women's formulas, let's explore what testosterone does in the body -- and why it's so important for both men and women. The 30,000 Mile Tune-Up: Hormonal Changes As men and women enter their 30's, profound changes begin to take place in their bodies. If not addressed (that's the 30,000 mile tune-up thing), these changes can lead to, among other things: • Decreased energy and zest for life • Loss of muscle tone and increased fat • Circulatory problems and decreased libido But it doesn't have to be this way. Let me explain. Hormonal Imbalance Hormones are the body's chemical messenger system. They tell the various cells of the body what to do - - and when to do it -- by attaching to specific receptor sites on individual cells. Problems occur when the various hormones get out of balance.
    [Show full text]
  • Failure of Vitamin B6 to Reverse the L-Dopa Effect in Patients on a Dopa Decarboxylase Inhibitor
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.34.6.682 on 1 December 1971. Downloaded from J. Neurol. Neurosurg. Psychiat., 34, 682-686 Failure of vitamin B6 to reverse the L-dopa effect in patients on a dopa decarboxylase inhibitor HAROLD L. KLAWANS, STEVEN P. RINGEL. AND DAVID M. SHENKER From the Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612, USA SUMMARY Seven patients with Parkinsonism previously on L-dopa were placed on a regimen of L-dopa and alpha methyl dopa hydrazine (a dopa decarboxylase inhibitor). Two of these patients had previously shown marked clinical deterioration of the L-dopa improvement when given pyrid- oxine. None of the seven patients receiving alpha methyl dopa hydrazine demonstrated any change in their condition when given pyridoxine. The failure of vitamin B6 to reverse the clinical effect of L-dopa in patients receiving both L-dopa and a peripheral dopa decarboxylase inhibitor suggests that reversal of the L-dopa effect induced by vitamin B6 is due to increasing the activity of the enzyme dopa decarboxylase outside the central nervous system. guest. Protected by copyright. In patients with Parkinsonism receiving L-dopa hydrazine). These observations help to explain the (L-3, 4-dihydroxyphenylalanine), vitamin B6 has paradoxical effects of large amounts of pyridoxine recently been shown to cause a loss or reversal of in patients receiving L-dopa. the L-dopa effect (Duvoisin, Yahr, and Cote, 1969; Yahr, Duvoisin, Schear, Barrett, and Hoehn, METHODS AND RESULTS 1970). This was discovered when Duvoisin et al. (1969) gave vitamin B6 to patients receiving L-dopa Seven patients with Parkinsonism who had been on in an attempt to increase formation of dopamine L-dopa for at least one year were included in this from L-dopa within the central nervous system (CNS) study.
    [Show full text]
  • S1 Table. List of Medications Analyzed in Present Study Drug
    S1 Table. List of medications analyzed in present study Drug class Drugs Propofol, ketamine, etomidate, Barbiturate (1) (thiopental) Benzodiazepines (28) (midazolam, lorazepam, clonazepam, diazepam, chlordiazepoxide, oxazepam, potassium Sedatives clorazepate, bromazepam, clobazam, alprazolam, pinazepam, (32 drugs) nordazepam, fludiazepam, ethyl loflazepate, etizolam, clotiazepam, tofisopam, flurazepam, flunitrazepam, estazolam, triazolam, lormetazepam, temazepam, brotizolam, quazepam, loprazolam, zopiclone, zolpidem) Fentanyl, alfentanil, sufentanil, remifentanil, morphine, Opioid analgesics hydromorphone, nicomorphine, oxycodone, tramadol, (10 drugs) pethidine Acetaminophen, Non-steroidal anti-inflammatory drugs (36) (celecoxib, polmacoxib, etoricoxib, nimesulide, aceclofenac, acemetacin, amfenac, cinnoxicam, dexibuprofen, diclofenac, emorfazone, Non-opioid analgesics etodolac, fenoprofen, flufenamic acid, flurbiprofen, ibuprofen, (44 drugs) ketoprofen, ketorolac, lornoxicam, loxoprofen, mefenamiate, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, pranoprofen, proglumetacin, sulindac, talniflumate, tenoxicam, tiaprofenic acid, zaltoprofen, morniflumate, pelubiprofen, indomethacin), Anticonvulsants (7) (gabapentin, pregabalin, lamotrigine, levetiracetam, carbamazepine, valproic acid, lacosamide) Vecuronium, rocuronium bromide, cisatracurium, atracurium, Neuromuscular hexafluronium, pipecuronium bromide, doxacurium chloride, blocking agents fazadinium bromide, mivacurium chloride, (12 drugs) pancuronium, gallamine, succinylcholine
    [Show full text]
  • Blood Thinners These Medications Require up to 2 Weeks of Discontinued Use Prior to a Myelogram Procedure
    MEDICATIONS TO AVOID PRE & POST MYELOGRAMS Radiocontrast agents used in myelography have the ability to lower the seizure threshold and when used with other drugs that also have this ability, may lead to convulsions. Drugs that possess the ability to lower seizure threshold should be discontinued at least 48 hours prior to myelography if possible and should not be resumed until at least 24 hours post-procedure. Drugs are listed below. ***Always consult with your prescribing physician prior to stoppage of your medication. Phenothiazines Antidepressants MAO Inhibitors Acetophenazine (Tindal) Amitriptyline (Elavil) Furazolidone (Furoxone) Chlorpromazine (Thorazine) Amoxapine (Asendin) Isocarboxazid (Marplan) Promethazine (Phenergan) Bupropion *(Welbutrin, Zyban) Pargyline (Eutonyl) Ethopropazine (Parsidol) Clomipramine (Anafranil, Placil) Phenelzine (Nardil) Fluphenazine (Prolixin) Desipramine (Norapramin) Procarbazine (Matulane) Mesoridazine (Serentil) Doxepin (Sinequan) Tranlcypromine (Parnate) Methdilazine (Tacaryl) Imipramine (Tofranil) Perphenazine (Trilafon) Maprotiline (Ludiomil) CNS Stimulants Proclorperazine (Compazine) Nortriptyline (Pamelor) Amphetamines Promazine (Sparine) Protriptyline (Vivactil) Pemoline (Cylert) Promethazine (Phenergan) Trimipramine (Surmontil) Thiethylperazine (Torecan) Thioridazine (Mellaril) Combination Antidepressants Trifluoperazine (Stelazine) Amitriptyline + Chlordiazepoxide (Limbitrol DS) Triflupromazine (Vesprin) Amitriptyline + Perphenazine (Triavil) Largon Levoprome Miscellaneous Antipsychotics
    [Show full text]
  • Antipsychotics
    Antipsychotics If you experience psychosis as part of an illness, you may be offered antipsychotic medication. Antipsychotics are generally used to treat psychosis, but are also used to treat bipolar disorder and depression. This factsheet explains more about antipsychotic medication. There are two types of antipsychotics – ‘first generation’ or ‘typical’ (older medications) and ‘second generation’ or ‘atypical’ (newer medications). Antipsychotics affect people differently. If you take antipsychotics then you may get side effects. It can take some time to find the right medication. If you are taking an antipsychotic which you feel is not working, or if the side effects are difficult to live with, then you should discuss this with your GP or psychiatrist. You should not stop taking antipsychotics suddenly. Your antipsychotics can interact with other medications. It is important that your doctor is aware of all the medicine you are taking. This factsheet covers: 1. What are antipsychotics? 2. Are there different types of antipsychotics? 3. Are there any side effects? 4. What if I want to stop taking antipsychotics? 5. Do antipsychotics affect other medication? 6. Does alcohol affect my antipsychotics? 7. Can I drive when taking antipsychotics? 8. What else should I consider before taking antipsychotics? Top 1. What are antipsychotics? Psychosis is a medical term. If you have psychosis, you might see or hear things (hallucinations), or have ideas or beliefs that are not shared by other people around you (delusions). Some people describe it as a ‘break from reality’. Doctors may also describe it as ‘psychotic symptoms’, a ‘psychotic episode’ or a ‘psychotic experience’.
    [Show full text]
  • Screening of 300 Drugs in Blood Utilizing Second Generation
    Forensic Screening of 300 Drugs in Blood Utilizing Exactive Plus High-Resolution Accurate Mass Spectrometer and ExactFinder Software Kristine Van Natta, Marta Kozak, Xiang He Forensic Toxicology use Only Drugs analyzed Compound Compound Compound Atazanavir Efavirenz Pyrilamine Chlorpropamide Haloperidol Tolbutamide 1-(3-Chlorophenyl)piperazine Des(2-hydroxyethyl)opipramol Pentazocine Atenolol EMDP Quinidine Chlorprothixene Hydrocodone Tramadol 10-hydroxycarbazepine Desalkylflurazepam Perimetazine Atropine Ephedrine Quinine Cilazapril Hydromorphone Trazodone 5-(p-Methylphenyl)-5-phenylhydantoin Desipramine Phenacetin Benperidol Escitalopram Quinupramine Cinchonine Hydroquinine Triazolam 6-Acetylcodeine Desmethylcitalopram Phenazone Benzoylecgonine Esmolol Ranitidine Cinnarizine Hydroxychloroquine Trifluoperazine Bepridil Estazolam Reserpine 6-Monoacetylmorphine Desmethylcitalopram Phencyclidine Cisapride HydroxyItraconazole Trifluperidol Betaxolol Ethyl Loflazepate Risperidone 7(2,3dihydroxypropyl)Theophylline Desmethylclozapine Phenylbutazone Clenbuterol Hydroxyzine Triflupromazine Bezafibrate Ethylamphetamine Ritonavir 7-Aminoclonazepam Desmethyldoxepin Pholcodine Clobazam Ibogaine Trihexyphenidyl Biperiden Etifoxine Ropivacaine 7-Aminoflunitrazepam Desmethylmirtazapine Pimozide Clofibrate Imatinib Trimeprazine Bisoprolol Etodolac Rufinamide 9-hydroxy-risperidone Desmethylnefopam Pindolol Clomethiazole Imipramine Trimetazidine Bromazepam Felbamate Secobarbital Clomipramine Indalpine Trimethoprim Acepromazine Desmethyltramadol Pipamperone
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]